170 related articles for article (PubMed ID: 32084531)
1. Regulation of KLF4 by posttranslational modification circuitry in endocrine resistance.
Zhou Z; Song X; Chi JJ; Gius DR; Huang Y; Cristofanilli M; Wan Y
Cell Signal; 2020 Jun; 70():109574. PubMed ID: 32084531
[TBL] [Abstract][Full Text] [Related]
2. KLF4 overcomes tamoxifen resistance by suppressing MAPK signaling pathway and predicts good prognosis in breast cancer.
Jia Y; Zhou J; Luo X; Chen M; Chen Y; Wang J; Xiong H; Ying X; Hu W; Zhao W; Deng W; Wang L
Cell Signal; 2018 Jan; 42():165-175. PubMed ID: 28988130
[TBL] [Abstract][Full Text] [Related]
3. Novel insight into KLF4 proteolytic regulation in estrogen receptor signaling and breast carcinogenesis.
Hu D; Zhou Z; Davidson NE; Huang Y; Wan Y
J Biol Chem; 2012 Apr; 287(17):13584-97. PubMed ID: 22389506
[TBL] [Abstract][Full Text] [Related]
4. Reciprocal regulation of integrin β4 and KLF4 promotes gliomagenesis through maintaining cancer stem cell traits.
Ma B; Zhang L; Zou Y; He R; Wu Q; Han C; Zhang B
J Exp Clin Cancer Res; 2019 Jan; 38(1):23. PubMed ID: 30658712
[TBL] [Abstract][Full Text] [Related]
5. Estrogen receptor α is a novel target of the Von Hippel-Lindau protein and is responsible for the proliferation of VHL-deficient cells under hypoxic conditions.
Jung YS; Lee SJ; Yoon MH; Ha NC; Park BJ
Cell Cycle; 2012 Dec; 11(23):4462-73. PubMed ID: 23159849
[TBL] [Abstract][Full Text] [Related]
6. FBXO32 suppresses breast cancer tumorigenesis through targeting KLF4 to proteasomal degradation.
Zhou H; Liu Y; Zhu R; Ding F; Wan Y; Li Y; Liu Z
Oncogene; 2017 Jun; 36(23):3312-3321. PubMed ID: 28068319
[TBL] [Abstract][Full Text] [Related]
7. The expression of the von Hippel-Lindau gene product and its impact on invasiveness of human breast cancer cells.
Zia MK; Rmali KA; Watkins G; Mansel RE; Jiang WG
Int J Mol Med; 2007 Oct; 20(4):605-11. PubMed ID: 17786294
[TBL] [Abstract][Full Text] [Related]
8. miR-484 suppresses endocrine therapy-resistant cells by inhibiting KLF4-induced cancer stem cells in estrogen receptor-positive cancers.
Wei Y; Li H; Qu Q
Breast Cancer; 2021 Jan; 28(1):175-186. PubMed ID: 32865695
[TBL] [Abstract][Full Text] [Related]
9. Interplay between arginine methylation and ubiquitylation regulates KLF4-mediated genome stability and carcinogenesis.
Hu D; Gur M; Zhou Z; Gamper A; Hung MC; Fujita N; Lan L; Bahar I; Wan Y
Nat Commun; 2015 Sep; 6():8419. PubMed ID: 26420673
[TBL] [Abstract][Full Text] [Related]
10. Regulation of KLF4 turnover reveals an unexpected tissue-specific role of pVHL in tumorigenesis.
Gamper AM; Qiao X; Kim J; Zhang L; DeSimone MC; Rathmell WK; Wan Y
Mol Cell; 2012 Jan; 45(2):233-43. PubMed ID: 22284679
[TBL] [Abstract][Full Text] [Related]
11. The deubiquitinase USP10 regulates KLF4 stability and suppresses lung tumorigenesis.
Wang X; Xia S; Li H; Wang X; Li C; Chao Y; Zhang L; Han C
Cell Death Differ; 2020 Jun; 27(6):1747-1764. PubMed ID: 31748695
[TBL] [Abstract][Full Text] [Related]
12. ATXN3 promotes breast cancer metastasis by deubiquitinating KLF4.
Zou H; Chen H; Zhou Z; Wan Y; Liu Z
Cancer Lett; 2019 Dec; 467():19-28. PubMed ID: 31563563
[TBL] [Abstract][Full Text] [Related]
13. von Hippel-Lindau protein promotes Skp2 destabilization on DNA damage.
Roe JS; Kim HR; Hwang IY; Cho EJ; Youn HD
Oncogene; 2011 Jul; 30(28):3127-38. PubMed ID: 21358672
[TBL] [Abstract][Full Text] [Related]
14. Identification of cyclin D1 and other novel targets for the von Hippel-Lindau tumor suppressor gene by expression array analysis and investigation of cyclin D1 genotype as a modifier in von Hippel-Lindau disease.
Zatyka M; da Silva NF; Clifford SC; Morris MR; Wiesener MS; Eckardt KU; Houlston RS; Richards FM; Latif F; Maher ER
Cancer Res; 2002 Jul; 62(13):3803-11. PubMed ID: 12097293
[TBL] [Abstract][Full Text] [Related]
15. Von Hippel-Lindau (VHL) small-molecule inhibitor binding increases stability and intracellular levels of VHL protein.
Frost J; Rocha S; Ciulli A
J Biol Chem; 2021 Aug; 297(2):100910. PubMed ID: 34174286
[TBL] [Abstract][Full Text] [Related]
16. A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma.
Suwaki N; Vanhecke E; Atkins KM; Graf M; Swabey K; Huang P; Schraml P; Moch H; Cassidy AM; Brewer D; Al-Lazikani B; Workman P; De-Bono J; Kaye SB; Larkin J; Gore ME; Sawyers CL; Nelson P; Beer TM; Geng H; Gao L; Qian DZ; Alumkal JJ; Thomas G; Thomas GV
Sci Transl Med; 2011 Jun; 3(85):85ra47. PubMed ID: 21632985
[TBL] [Abstract][Full Text] [Related]
17. Oxygen-dependent Regulation of Erythropoietin Receptor Turnover and Signaling.
Heir P; Srikumar T; Bikopoulos G; Bunda S; Poon BP; Lee JE; Raught B; Ohh M
J Biol Chem; 2016 Apr; 291(14):7357-72. PubMed ID: 26846855
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of STAT3 enhances sensitivity to tamoxifen in tamoxifen-resistant breast cancer cells.
Moon SY; Lee H; Kim S; Hong JH; Chun SH; Lee HY; Kang K; Kim HS; Won HS; Ko YH
BMC Cancer; 2021 Aug; 21(1):931. PubMed ID: 34407787
[TBL] [Abstract][Full Text] [Related]
19. Phosphorylation of the von Hippel-Lindau protein (VHL) by protein kinase CK2 reduces its protein stability and affects p53 and HIF-1alpha mediated transcription.
Ampofo E; Kietzmann T; Zimmer A; Jakupovic M; Montenarh M; Götz C
Int J Biochem Cell Biol; 2010 Oct; 42(10):1729-35. PubMed ID: 20637892
[TBL] [Abstract][Full Text] [Related]
20. Ubiquitin/SUMO modification regulates VHL protein stability and nucleocytoplasmic localization.
Cai Q; Robertson ES
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20844582
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
